الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 83 |  |  |
| | | from | 83 | | |
Abstract
Non-small-cell lung cancer (NSCLC), a common type of lung cancer, is among the most frequently diagnosed types of cancer and is a leading cause of mortality worldwide. However, unfortunately, most patients with NSCLC are diagnosed at advanced stages.
Detecting non-small-cell lung cancer at an early stage has become a great challenge due to the lack of a specific noninvasive marker. MicroRNAs are small, noncoding RNA molecules that play a role in carcinogenesis and cancer progression, as indicated by their abnormal expression in the patients’ plasma. Herein, we investigated the plasma level of circulating miRNA-30a and miRNA-221 as noninvasive markers for early detection of non-small-cell lung cancer.
This study was aimed to investigate the expression pattern of miRNA-30a and miRNA-221 in the plasma of NSCLC patients and to evaluate the potential of plasma miRNA-30a and miRNA-221 levels as novel tumor biomarkers for NSCLC diagnosis and prognosis.
Blood samples were collected from 70 patients with NSCLC and 34 healthy control subjects. The lung cancer patients included 35 patients with squamous cell carcinoma, 24 with adenocarcinoma and 11 with large cell carcinoma. These patients were at various clinical stages, including 28 with stage II disease and 42 with stage III disease. The patients were classified according to TNM status: 31 with intrathoracic lymph node metastasis and 39 without metastasis
The results of the present study demonstrated that the expression levels of circulating plasma miRNA-30a and miRNA-221 were significantly higher in the NSCLC patients than in healthy controls (P<0.01, P=0.036). There was no significant difference in the miRNA-30a and miRNA-221 plasma levels in patients with stage II and stage III non-small cell lung cancer. Results showed that the plasma miRNA-30a and miRNA-221 levels were higher in the lung cancer patients with metastasis than in lung cancer patients without metastasis. However, the difference was not statistically significant (P=0.1 and P=0.057, respectively). There was a significant difference between squamous cell carcinoma , adenocarcinoma and large cell carcinoma patients in plasma miRNA-30a levels (p=0.03). While the difference in miRNA-221 plasma levels between SCC, Adenocarcinoma and bronchogenic carcinoma patients was not statistically significant (p=0.9). ROC curve analysis for miRNA-30a and miRNA-221 showed that the best cut off value for miRNA-30a 27.75, with a sensitivity of 80 % and a specificity of 60 %, while, the best cut off value for miRNA-221 was 34.84, with a sensitivity of 60 % and a specificity of 40 %. This indicates that miRNA-30a was more specific and sensitive than miRNA-221 as a biomarker for detection of non-small cell lung cancer. The results of our study provide a highly significant difference between both miRNA-30a and miRNA-221 expression between lung cancer patients and healthy controls. This study revealed that miRNA-221 and miRNA-30a may be sensitive and specific biomarkers for early NSCLC diagnosis.